BioVersys AG, a clinical-stage biopharmaceutical company developing novel antibacterials for multidrug-resistant infections, announced the publication of two Phase 1 clinical pharmacology studies of its lead asset BV100 in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy. The data, disclosed via NEWMEDIAWIRE, provide key pharmacological support for BV100's use in severe pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), a pathogen with limited treatment options and high mortality.
The lung penetration study, published with DOI 10.1016/j.ijantimicag.2026.108014, enrolled 36 healthy male participants who received intravenous BV100 300 mg every 12 hours for four days. Rifabutin concentrations in lung fluid and alveolar macrophages exceeded plasma levels at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively. Repeated dosing was well tolerated. The authors concluded these pulmonary exposures offer a strong pharmacological rationale for further clinical evaluation in severe CRAB pneumonia.
The drug-drug interaction paper, published with DOI: 10.1093/jac/dkag317, showed across two Phase 1 studies that BV100 is a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold when co-administered with itraconazole. This profile is milder than that of rifampicin, a strong CYP3A inducer. BV100 was safe and well tolerated in both studies.
Dr. Glenn Dale, Chief Development Officer and co-author, said the papers address questions that matter most for an intravenous antibiotic in critically ill pneumonia patients, noting BV100 has very good distribution in lung fluid and alveolar macrophages and a mild, manageable drug-interaction profile. Dr. Marc Gitzinger, CEO and founder, added that carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease and that these data strengthen the scientific basis for BV100 therapy in CRABC pneumonia.
These findings matter because critically ill patients often receive many medicines, so a milder interaction profile reduces the risk of complications. BV100 is being studied in the pivotal Phase 3 registrational trial RIV-TARGET and the Phase 2b RIV-CARE trial. Enrollment in RIV-TARGET is ongoing, with topline data anticipated in early 2028. BV100 received Fast Track Designation from the US FDA in September 2026, under the Qualified Infectious Disease Product designation granted in 2019.
Carbapenem-resistant A. baumannii infections are estimated to surpass one million annually in hospitals globally, with mortality rates up to 50% due to limited treatment options, according to BioVersys. For clinicians and patients, the publications reinforce the potential of BV100 as a much-needed new option. The company's website is www.bioversys.com.
